624 related articles for article (PubMed ID: 21893541)
1. Tuberculosis vaccines: beyond bacille Calmette-Guerin.
McShane H
Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2782-9. PubMed ID: 21893541
[TBL] [Abstract][Full Text] [Related]
2. Immunization strategies against pulmonary tuberculosis: considerations of T cell geography.
Horvath CN; Xing Z
Adv Exp Med Biol; 2013; 783():267-78. PubMed ID: 23468114
[TBL] [Abstract][Full Text] [Related]
3. Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis.
Xing Z; Charters TJ
Expert Rev Vaccines; 2007 Aug; 6(4):539-46. PubMed ID: 17669008
[TBL] [Abstract][Full Text] [Related]
4. Next-Generation Vaccines Based on Bacille Calmette-Guérin.
Nieuwenhuizen NE; Kaufmann SHE
Front Immunol; 2018; 9():121. PubMed ID: 29459859
[TBL] [Abstract][Full Text] [Related]
5. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
Front Immunol; 2018; 9():2371. PubMed ID: 30386336
[TBL] [Abstract][Full Text] [Related]
6. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?
Moliva JI; Turner J; Torrelles JB
Vaccine; 2015 Sep; 33(39):5035-41. PubMed ID: 26319069
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in tuberculosis vaccines.
Haile M; Källenius G
Curr Opin Infect Dis; 2005 Jun; 18(3):211-5. PubMed ID: 15864097
[TBL] [Abstract][Full Text] [Related]
8. Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates.
Méndez-Samperio P
Scand J Immunol; 2019 Oct; 90(4):e12772. PubMed ID: 31055842
[TBL] [Abstract][Full Text] [Related]
9. Recombinant live vaccine candidates against tuberculosis.
Kaufmann SH; Gengenbacher M
Curr Opin Biotechnol; 2012 Dec; 23(6):900-7. PubMed ID: 22483201
[TBL] [Abstract][Full Text] [Related]
10. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z
J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375
[TBL] [Abstract][Full Text] [Related]
11. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
[TBL] [Abstract][Full Text] [Related]
12. Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.
Zhang Y; Feng L; Li L; Wang D; Li C; Sun C; Li P; Zheng X; Liu Y; Yang W; Niu X; Zhong N; Chen L
Hum Vaccin Immunother; 2015; 11(7):1803-13. PubMed ID: 26076321
[TBL] [Abstract][Full Text] [Related]
13. Clinical Testing of Tuberculosis Vaccine Candidates.
Hatherill M; Tait D; McShane H
Microbiol Spectr; 2016 Oct; 4(5):. PubMed ID: 28087924
[TBL] [Abstract][Full Text] [Related]
14. Novel vaccination strategies based on recombinant Mycobacterium bovis BCG.
Dietrich G; Viret JF; Hess J
Int J Med Microbiol; 2003 Feb; 292(7-8):441-51. PubMed ID: 12635927
[TBL] [Abstract][Full Text] [Related]
15. Bacille Calmette-Guérin Vaccine Strain Modulates the Ontogeny of Both Mycobacterial-Specific and Heterologous T Cell Immunity to Vaccination in Infants.
Kiravu A; Osawe S; Happel AU; Nundalall T; Wendoh J; Beer S; Dontsa N; Alinde OB; Mohammed S; Datong P; Cameron DW; Rosenthal K; Abimiku A; Jaspan HB; Gray CM
Front Immunol; 2019; 10():2307. PubMed ID: 31649662
[TBL] [Abstract][Full Text] [Related]
16. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
[TBL] [Abstract][Full Text] [Related]
17. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
[TBL] [Abstract][Full Text] [Related]
18. Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.
Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Eum SY; Cho SN; Shin SJ
PLoS One; 2015; 10(10):e0141577. PubMed ID: 26509812
[TBL] [Abstract][Full Text] [Related]
19. Heterologous Boost Following
Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
Front Immunol; 2018; 9():2439. PubMed ID: 30425711
[TBL] [Abstract][Full Text] [Related]
20. Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.
Zhang M; Dong C; Xiong S
Hum Vaccin Immunother; 2017 Apr; 13(4):816-822. PubMed ID: 27960596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
